Press release
Intrahepatic Cholangiocarcinoma Treatment Market size is expected to grow owing to the launch of emerging therapies by 2034, estimates DelveInsight
The Intrahepatic Cholangiocarcinoma Market is an evolving segment of the global healthcare landscape, driven by the increasing Intrahepatic Cholangiocarcinoma prevalence of the disorder and the continuous development of innovative treatment options. The Intrahepatic Cholangiocarcinoma Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Intrahepatic Cholangiocarcinoma Market with DelveInsight's In-Depth Report @ Intrahepatic Cholangiocarcinoma Market Size [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Intrahepatic Cholangiocarcinoma Market Report
* In November 2024:- Jazz Pharmaceuticals- The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
* In 2023, the US accounted for ~30% of the total incident cases of cholangiocarcinoma in the 7MM.
* As per the analysis, there were ~6,400 cases of intrahepatic cholangiocarcinoma in Japan, in 2023.
* In 2023, the mutation-specific cases of intrahepatic cholangiocarcinoma were highest in TP53 mutations, followed by KRAS mutations in the US.
* The leading intrahepatic cholangiocarcinoma companies such as Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd. , and others.
* The Intrahepatic cholangiocarcinoma therapies such as VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab) , and others.
Stay ahead in the Intrahepatic Cholangiocarcinoma Therapeutics Market with DelveInsight's Strategic Report @ Intrahepatic Cholangiocarcinoma Market Outlook [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Intrahepatic Cholangiocarcinoma Epidemiology Segmentation in the 7MM
* Total Intrahepatic Cholangiocarcinoma Incident Cases
* Total Intrahepatic Cholangiocarcinoma Incident Cases
* Intrahepatic Cholangiocarcinoma Mutation-specific Cases
* Intrahepatic Cholangiocarcinoma Age-specific Cases
* Intrahepatic Cholangiocarcinoma Stage-specific Cases
* Total Intrahepatic Cholangiocarcinoma Treated Cases
Download the report to understand which factors are driving Intrahepatic Cholangiocarcinoma epidemiology trends @ Intrahepatic Cholangiocarcinoma Prevalence [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Intrahepatic Cholangiocarcinoma Marketed Drugs
* PEMAZYRE (pemigatinib): Incyte Corporation
PEMAZYRE (pemigatinib) is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
* ROZLYTREK (entrectinib): Roche
ROZLYTREK (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy..
* TIBSOVO (ivosidenib): Servier/Agios Pharmaceuticals
TIBSOVO (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test, for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. The recommended dosage of TIBSOVO is 500 mg taken orally once daily until disease progression or unacceptable toxicity.
Intrahepatic Cholangiocarcinoma Emerging Drugs
* CTX-009: Compass Therapeutics
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.
* Tinengotinib: TransThera Sciences
Tinengotinib is an innovative, global Phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors. It was granted the ODD and FTD by the FDA for the treatment of cholangiocarcinoma.
* Silmitasertib (CX-4945): Senhwa Biosciences
Silmitasertib (CX-4945), a synthetically derived small molecule, is provided as a sodium salt in hard gelatin capsule shells with oral administration. CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination.
Get In-Depth Knowledge on Intrahepatic Cholangiocarcinoma Market Trends and Forecasts with DelveInsight @ Intrahepatic Cholangiocarcinoma Treatment Market [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Intrahepatic Cholangiocarcinoma Market Outlook
The Intrahepatic Cholangiocarcinoma market is evolving with promising advancements in targeted and personalized treatments. Although intrahepatic cholangiocarcinoma remains challenging due to late diagnosis and its rarity, the development of drugs targeting FGFR2 and IDH-1 mutations offers new hope. Increased research, improved molecular diagnostics, and the rise of precision medicine are driving market growth. However, high treatment costs and recruitment difficulties in clinical trials are ongoing challenges. The future outlook is positive, with expectations for expanded treatment options and improved patient outcomes as new therapies gain approval and become available.
Scope of the Intrahepatic Cholangiocarcinoma Market
* Coverage- 7MM
* Intrahepatic cholangiocarcinoma companies- Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd., and others are developing novel intrahepatic cholangiocarcinoma drugs that can be available in the intrahepatic cholangiocarcinoma market in the coming years.
* Intrahepatic cholangiocarcinoma Therapies- VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab), and others.
* Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
* Intrahepatic Cholangiocarcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight's Comprehensive Intrahepatic Cholangiocarcinoma Market Report @ Intrahepatic Cholangiocarcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary of Intrahepatic Cholangiocarcinoma
3. Competitive Intelligence Analysis for Intrahepatic Cholangiocarcinoma
4. Intrahepatic Cholangiocarcinoma: Market Overview at a Glance
5. Intrahepatic Cholangiocarcinoma: Disease Background and Overview
6. Patient Journey
7. Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Intrahepatic Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Intrahepatic Cholangiocarcinoma Treatment
11. Intrahepatic Cholangiocarcinoma Marketed Products
12. Intrahepatic Cholangiocarcinoma Emerging Therapies
13. Intrahepatic Cholangiocarcinoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Intrahepatic Cholangiocarcinoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intrahepatic-cholangiocarcinoma-treatment-market-size-is-expected-to-grow-owing-to-the-launch-of-emerging-therapies-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Treatment Market size is expected to grow owing to the launch of emerging therapies by 2034, estimates DelveInsight here
News-ID: 3736668 • Views: …
More Releases from ABNewswire
Lenox Hill Hardware Store & Housewares Destination: S. Feldman Housewares Expand …
S. Feldman Housewares, the family-run Carnegie Hill favorite since 1929, has expanded its in-store selection to make it even easier for Upper East Side residents to find everyday essentials in one stop. From kitchen staples and home organization to hardware basics and those hard-to-find problem solvers, the store's Madison Avenue location continues to be a trusted resource for neighbors who appreciate knowledgeable service and genuinely helpful advice.
NEW YORK, NY -…
Insurance Industry Veteran Sounds the Alarm on Career Risk Facing New York Medic …
EAST AURORA, NY - As New York State's healthcare system continues to rely heavily on medical residents and early-career physicians, a growing financial risk is quietly emerging behind hospital doors: many of these professionals are one illness or injury away from losing their income with limited protection in place.
Kasey Labrie, a New York-based insurance agent and agency owner, is bringing attention to what she calls a "critical blind spot" in…
Chicago Family Law Attorneys Molly E. Caesar and Michael Ian Bender Announce Lau …
Chicago family law attorneys Molly E. Caesar and Michael Ian Bender have announced the launch of a newly redesigned website for Caesar & Bender, LLP [https://www.caesarbenderlaw.com/]. The new site is built to help individuals and families in the Chicago area access clear legal information and take the first step toward resolving family law matters with confidence.
Created with usability in mind, the website offers a streamlined experience for those handling sensitive…
Why More Augusta GA Area Homeowners Are Rethinking Renovation - and Choosing a P …
As homeowners across the CSRA rethink how their homes function, feel, and grow with their families, one question continues to rise to the surface: Who can I trust as my home renovation contractor? For many homeowners in the Augusta and Evans GA area, the answer has become Impact Roofing & Construction.
Rather than chasing short-term design trends or surface-level upgrades, Impact Roofing & Construction [https://impactroofingconstruction.s3.us-east-1.amazonaws.com/press/GeneralContractor-AugustaGA.html] approaches renovation with a long-term mindset-helping…
More Releases for Intrahepatic
Intrahepatic Cholangiocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 18+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report…
Progressive Familial Intrahepatic Cholestasis (PFIC) Market is projected to reac …
The global Progressive Familial Intrahepatic Cholestasis (PFIC) Market was valued at USD 412 million in 2024 and is projected to reach USD 1.02 billion by 2034, growing at a CAGR of 9.4% during the forecast period (2025-2034). Market growth is driven by rising diagnosis supported by genetic testing, increasing awareness of rare pediatric cholestatic disorders, expanding availability of targeted pharmacologic therapies, and ongoing research into gene-based treatments.
Download Full PDF Sample…
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Growth, Trends, Cons …
Introduction
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of rare, inherited liver disorders characterized by defective bile secretion, leading to chronic cholestasis, liver damage, and progressive liver failure. PFIC typically manifests in infancy or early childhood and, without intervention, often requires liver transplantation at a young age.
For decades, treatment options were limited to symptomatic relief and surgical interventions. However, with the approval of bile acid transporter inhibitors, alongside the emergence…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Ta …
ChatGPT said: The intrahepatic cholangiocarcinoma (iCCA) pipeline is growing steadily, with over 18 companies focused on targeted and immunotherapeutic strategies. Key advances include FGFR2 fusions, IDH1/2 mutations, and HER2 amplifications, driving precision oncology in this aggressive liver cancer. Approvals of FGFR inhibitors like Pemazyre and Truseltiq have advanced biomarker-driven second-line treatments.
DelveInsight's "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a detailed analysis of the therapeutic development landscape for iCCA, a…
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Boston Scientific Corporati …
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. It involves creating a shunt between the portal and hepatic veins, bypassing the liver to reduce portal pressure. TIPS is performed under fluoroscopic guidance by interventional radiologists. It effectively alleviates symptoms and reduces the risk of complications associated with portal hypertension. TIPS is typically reserved for…
